Lance Miller to Middle Aged
This is a "connection" page, showing publications Lance Miller has written about Middle Aged.
Connection Strength
0.375
-
Moaven O, Su J, Jin G, Votanopoulos KI, Shen P, Mangieri C, O'Neill SS, Perry KC, Levine EA, Miller LD. Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. Ann Surg Oncol. 2020 Dec; 27(13):5016-5023.
Score: 0.066
-
Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD. Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. J Am Coll Surg. 2016 Apr; 222(4):493-503.
Score: 0.048
-
Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013 Apr 29; 14(4):R34.
Score: 0.040
-
Su J, Jin G, Votanopoulos KI, Craddock L, Shen P, Chou JW, Qasem S, O'Neill SS, Perry KC, Miller LD, Levine EA. Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2020 May; 27(5):1439-1447.
Score: 0.016
-
Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385.
Score: 0.016
-
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar; 34(1):90-97.
Score: 0.015
-
Dotson T, Bellinger C, Su J, Hansen K, Parks GE, Cappellari JO, Craddock L, Clark H, Howard C, Petty WJ, Prakash B, Watabe K, Chan M, Hovda J, Miller LD, Ruiz J. Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). Lung Cancer. 2019 01; 127:6-11.
Score: 0.015
-
Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct; 60(10):1043-1051.
Score: 0.015
-
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.
Score: 0.014
-
Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. Oncologist. 2018 04; 23(4):481-488.
Score: 0.014
-
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.
Score: 0.013
-
Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. J Am Soc Nephrol. 2017 Apr; 28(4):1093-1105.
Score: 0.013
-
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol. 2015 Sep; 124(3):447-53.
Score: 0.012
-
Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. . 2015; 16(5):678-83.
Score: 0.011
-
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.
Score: 0.011
-
Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014 Sep; 119(2):429-35.
Score: 0.011
-
Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012 Jan 18; 104(2):133-46.
Score: 0.009
-
Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Régnard JF, Lim D, Koong HN, Agasthian T, Miller LD, Lim E, Camilleri-Broët S, Tan P. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res. 2011 Jun 01; 17(11):3542-50.
Score: 0.009
-
Alifano M, Souazé F, Dupouy S, Camilleri-Broët S, Younes M, Ahmed-Zaïd SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, Broët P, Miller LD, Gespach C, Regnard JF, Forgez P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010 Sep 01; 16(17):4401-10.
Score: 0.008
-
Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, Nakamura Y, Qi RZ, Miller LD, Liu ET, Wang LD, Li JL, Law S, Tsao SW, Lung ML. Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 2008 Feb 01; 122(3):587-94.
Score: 0.007
-
Yu K, Ganesan K, Miller LD, Tan P. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3288-96.
Score: 0.006
-
Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002 Jul 01; 62(13):3581-6.
Score: 0.005